NCT04492371

Brief Summary

Collect in an observational study the outcomes of COVID19 infection in MM patients across Europe.

Trial Health

93
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,054

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2020

Typical duration for all trials

Geographic Reach
8 countries

8 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2020

Completed
27 days until next milestone

First Submitted

Initial submission to the registry

July 28, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 30, 2020

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 18, 2022

Completed
1.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2024

Completed
Last Updated

March 5, 2024

Status Verified

March 1, 2024

Enrollment Period

2.1 years

First QC Date

July 28, 2020

Last Update Submit

March 4, 2024

Conditions

Multiple MyelomaCovid19Corona Virus Infection

Outcome Measures

Primary Outcomes (7)

  • Nature of COVID19

    The duration of infection.

    1 years

  • Costs related to COVID-19

    Costs related to Covid in terms of health resource needs.

    1 years

  • Systemic anti-cancer therapy subgroup

    Number of infection recovery for each systemic anti-cancer subgroup.

    1 years

  • Laboratory values collected at hospitalization

    Evaluate if recurring haematological and chemistry values are related to infection onset, better or poorer outcome.

    1 years

  • COVID-19 infection in myeloma patient subgroups

    Number of infection in each myeloma patient subgroups and evaluation of the number of recovery per subgroup.

    1 years

  • Incidence of COVID-19 infection in frail patients

    Number of frail patients with COVID-19 infection and resolution of it.

    1 years

  • Infection outcome in different countries

    Number of infection and outcome per country.

    1 years

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Multiple Myeloma patients with COVID-19 infection

You may qualify if:

  • Multiple Myeloma patients
  • COVID-19 infection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (8)

General Hopspital Vienna/Medical University

Vienna, Austria

Location

UCL Saint-Luc

Brussels, Belgium

Location

University Hospital Ostrava

Ostrava, Czechia

Location

University Hospital Würzburg

Würzburg, Germany

Location

Alexandra Clinical Terapeutics

Athens, Greece

Location

AOU Consorziale Policlinico di Bari

Bari, Italy

Location

Amsterdam UMC

Amsterdam, Netherlands

Location

St James's University Hospital

Leeds, United Kingdom

Location

MeSH Terms

Conditions

Multiple MyelomaCOVID-19Coronavirus Infections

Condition Hierarchy (Ancestors)

Neoplasms, Plasma CellNeoplasms by Histologic TypeNeoplasmsHemostatic DisordersVascular DiseasesCardiovascular DiseasesParaproteinemiasBlood Protein DisordersHematologic DiseasesHemic and Lymphatic DiseasesHemorrhagic DisordersLymphoproliferative DisordersImmunoproliferative DisordersImmune System DiseasesPneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Sponsor Type
NETWORK
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 28, 2020

First Posted

July 30, 2020

Study Start

July 1, 2020

Primary Completion

August 18, 2022

Study Completion

March 1, 2024

Last Updated

March 5, 2024

Record last verified: 2024-03

Locations

GR(1)BE(1)CZ(1)NL(1)DE(1)IT(1)GB(1)AU(1)